Paratek Pharmaceuticals (FRA:N4CN) Total Liabilities : €320.4 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Total Liabilities?

Paratek Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2023 was €320.4 Mil.

Paratek Pharmaceuticals's quarterly Total Liabilities declined from Dec. 2022 (€324.34 Mil) to Mar. 2023 (€317.44 Mil) but then increased from Mar. 2023 (€317.44 Mil) to Jun. 2023 (€320.43 Mil).

Paratek Pharmaceuticals's annual Total Liabilities increased from Dec. 2020 (€229.43 Mil) to Dec. 2021 (€275.82 Mil) and increased from Dec. 2021 (€275.82 Mil) to Dec. 2022 (€324.34 Mil).

Paratek Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Paratek Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Total Liabilities Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

222.05

261.65

229.43

275.82

324.34

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Liabilities	Get a 7-Day Free Trial															296.16	326.71	324.34	317.44	320.43

Paratek Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Paratek Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	35.294	+	(243.943	+	2.316
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	42.787)
	=	324.3

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	162.876	-	-161.464
	=	324.3

Paratek Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	187.017	+	(88.344	+	2.086
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	42.979)
	=	320.4

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	134.566	-	-185.86
	=	320.4

Paratek Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines